Chemwatch Australian MSDS 3826981 - FUJIFILM Australia

More documents

Recommendations

Info

FUJIFILM CP-49E P1 PART A SUCChemwatch Independent Material Safety Data SheetIssue Date: 15-Mar-2012 CHEMWATCH 38269819317SP(cs)Version No:2.0CD 2012/1 Page 6 of 10Section 10 - STABILITY AND REACTIVITYCONDITIONS CONTRIBUTING TO INSTABILITY• Presence of incompatible materials.• Product is considered stable.• Hazardous polymerisation will not occur.For incompatible materials - refer to Section 7 - Handling and Storage.Section 11 - TOXICOLOGICAL INFORMATIONPOTENTIAL HEALTH EFFECTSACUTE HEALTH EFFECTSSWALLOWED■ Accidental ingestion of the material may be damaging to the health of the individual.Sulfonamides and their derivatives can cause extensive kidney damage, and destroy red blood cells. Overdose may cause anaccumulation of acid in the blood or a diminished blood sugar level with confusion and coma resulting. Predisposed persons candevelop hypersensitivity reactions, including for topical application. Deaths have occurred due to hypersensitivity, anaemia,imbalances in blood cell distribution and kidney and liver damage. 2-5 grams can be fatal. Sulfonamides cross the placentalbarrier, are excreted in the breast milk and may produce adverse effects in the foetus/embryo and newborn, including loss ofcertain white blood cells causing immune function deficiency, anaemia, jaundice and kernicterus.EYE■ If applied to the eyes, this material causes severe eye damage.Eye drops with sulfonamides can cause local irritation, sensations of burning and stinging, blurred vision and loss of depthperception. The conjunctiva and cornea may become inflamed, and the cornea and lens may become clouded.SKIN■ This material can cause inflammation of the skin oncontact in some persons.The material may accentuate any pre-existing dermatitis condition.Entry into the blood-stream, through, for example, cuts, abrasions or lesions, may produce systemic injury with harmful effects.Examine the skin prior to the use of the material and ensure that any external damage is suitably protected.INHALED■ The material is not thought to produce either adverse health effects or irritation of the respiratory tract followinginhalation (as classified by EC Directives using animal models). Nevertheless, adverse systemic effects have been producedfollowing exposure of animals by at least one other route and good hygiene practice requires that exposure be kept to a minimumand that suitable control measures be used in an occupational setting.Not normally a hazard due to non-volatile nature of product.CHRONIC HEALTH EFFECTS■ Skin contact with the material is more likely to cause a sensitisation reaction in some persons compared to the generalpopulation.There has been some concern that this material can cause cancer or mutations but there is not enough data to make an assessment.Substance accumulation, in the human body, may occur and may cause some concern following repeated or long-term occupationalexposure.There is some evidence that inhaling this product is more likely to cause a sensitisation reaction in some persons compared tothe general population.Prolonged oral treatment with sulfonamides has caused nausea, vomiting, diarrhoea, abdominal pain, loss of appetite, inflammationof the mouth cavity, impaired folic acid absorption, exacerbation of porphyria, acidosis, liver damage with impaired bloodclotting, jaundice and inflammation of the pancreas. Effects on the kidney include blood and crystals in the urine, painful andfrequent urination or lack of urine with nitrogen retention. Nervous system symptoms include headache, drowsiness, troublesleeping, dizziness, ringing in the ears, hearing loss, depression, hallucinations, inco-ordination, paralysis of muscles,numbness in the extremities, spinal cord damage and inflammation, convulsions and unconsciousness. Effects on the blood include achange in blood cell distribution with loss of white blood cells and platelets, and anaemia, which Africans seem to be more proneto developing than Europeans. Cyanosis can occur owing to complexes being formed by haemoglobin. Eye effects include inflamedcornea and conjunctiva with eyelid swelling and in severe cases, fear of the light. Allergies and cross-sensitivity is common,and can cause itches, wheals and sometimes a severe red rash with blisters that is often fatal. This class of drugs can scar thecornea and conjunctiva, cause swelling around the eyes, painful and inflamed joints, reduced sperm counts, pneumonia, fever,chills, hair loss, inflammation of vessels, lupus, reduced lung function, infertility, hypothyroidism and goitre, and increasedurinary output. More seriously, the lungs may become permanently scarred and there may be irreversible damage to the nervoussystem and muscles. Inflammation of the skin has occurred after the drug is ingested and has travelled through the bloodstream.Skin effects often occur when there has been exposure in conjunction with UV light. Clothed areas are initially less likely to beaffected but may be in later stages. Rarely there may be persistence of inflammation on light contact even after the drug hasbeen removed.Repeated exposure to hydroxylamine and derivatives may result in respiratory sensitisation with asthma-like symptoms.continued...
FUJIFILM CP-49E P1 PART A SUCChemwatch Independent Material Safety Data SheetIssue Date: 15-Mar-2012 CHEMWATCH 38269819317SP(cs)Version No:2.0CD 2012/1 Page 7 of 10Section 11 - TOXICOLOGICAL INFORMATIONTOXICITY AND IRRITATION■ Contact allergies quickly manifest themselves as contact eczema, more rarely as urticaria or Quincke's oedema. The pathogenesisof contact eczema involves a cell-mediated (T lymphocytes) immune reaction of the delayed type. Other allergic skin reactions,e.g. contact urticaria, involve antibody-mediated immune reactions. The significance of the contact allergen is not simplydetermined by its sensitisation potential: the distribution of the substance and the opportunities for contact with it areequally important. A weakly sensitising substance which is widely distributed can be a more important allergen than one withstronger sensitising potential with which few individuals come into contact. From a clinical point of view, substances arenoteworthy if they produce an allergic test reaction in more than 1% of the persons tested.No significant acute toxicological data identified in literature search.Asthma-like symptoms may continue for months or even years after exposure to the material ceases. This may be due to a nonallergeniccondition known as reactive airways dysfunction syndrome (RADS) which can occur following exposure to high levels ofhighly irritating compound.Section 12 - ECOLOGICAL INFORMATIONToxic to soil organisms.This material and its container must be disposed of as hazardous waste.EcotoxicityIngredient Persistence: Persistence: Air Bioaccumulation MobilityWater/Soilpotassium carbonate No Data No DataAvailableAvailableEDTA tetrapotassium salt No Data No DataAvailableAvailabledisodium N, N- No Data No Databis(sulfonatoethyl)hydroxylamine Available AvailableN- [2- (4- amino- N- ethyl- m- HIGH No Data LOW MEDtoluidino)ethyl]methanesulfonamiAvailabledepotassium sulfate No Data No DataAvailableAvailablesodium hydroxide LOW No Data LOW HIGHAvailablepotassium hydroxide No Data No Data LOWAvailableAvailableSection 13 - DISPOSAL CONSIDERATIONS• Containers may still present a chemical hazard/ danger when empty.• Return to supplier for reuse/ recycling if possible.Otherwise:• If container can not be cleaned sufficiently well to ensure that residuals do not remain or if the container cannot be used tostore the same product, then puncture containers, to prevent re-use, and bury at an authorised landfill.• Where possible retain label warnings and MSDS and observe all notices pertaining to the product.Legislation addressing waste disposal requirements may differ by country, state and/ or territory. Each user must refer to lawsoperating in their area.A Hierarchy of Controls seems to be common - the user should investigate:• Reduction.• DO NOT allow wash water from cleaning or process equipment to enter drains.• It may be necessary to collect all wash water for treatment before disposal.• In all cases disposal to sewer may be subject to local laws and regulations and these should be considered first.• Where in doubt contact the responsible authority.• Recycle wherever possible.• Consult manufacturer for recycling options or consult local or regional waste management authority for disposal if no suitabletreatment or disposal facility can be identified.• Treat and neutralise at an approved treatment plant. Treatment should involve: Neutralisation followed by: burial in a landfillspecifically licenced to accept chemical and / or pharmaceutical wastes or Incineration in a licenced apparatus (afteradmixture with suitable combustible material)• Decontaminate empty containers. Observe all label safeguards until containers are cleaned and destroyed.continued...
Page 1: FUJIFILM CP-49E P1 PART A SUCChemwa
Page 4 and 5: FUJIFILM CP-49E P1 PART A SUCChemwa
Page 12 and 13: FUJIFILM CP-49E P1 PART B SUCChemwa

Chemwatch Australian MSDS 3826981 - FUJIFILM Australia

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?